Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/ExeR-1 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast Cancer
  • Disease: Cancer
  • Description: The MCF7/ExeR-1 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors.Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the steroidal AI exemestane allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Passage number: Passage 430 (AL3058, AL3059)
  • Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM exemestane.
  • Shipping conditions: Dry ice

Documentation

  • Available on request

References

  •   Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.
  •   Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
  •   Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
  •   New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.